Gen Z Tenant Finds Mold in Apartment, Fury Over Lease Company's Response
A South Carolina resident has horrified the internet after revealing the state of her mold-infested apartment, which her leasing agency claims is her fault.
Reddit user Mary, 27, from Downtown Charleston, recently took to social media to share several images of the mold that's covering her home and her belongings. The images show handbags, UGG boots, wine bottles, and walls with patches of mold growing on them.
Mary has lived in the unit for three years, and although it wasn't so bad for the first two years, things have really taken a turn in 2025. Mary told Newsweek that she previously noticed mold on shoes, purses and jackets that she barely wore, so she didn't think too much of it. But now, it's "even worse" and so many of her possessions have been devastated by mold.
"My mattress is covered in mold spores, as well as 80 percent of my purses, shoes, and jackets," Mary said. "My cat tree is covered, and I had to throw it out. Pretty much cotton is the only thing that doesn't have it. All my wooden furniture, like bookshelves and storage shelves, have spots. I've had to throw out so many odds and ends."
Mary's Ugg boots and a handbag with spots of mold.
Mary's Ugg boots and a handbag with spots of mold.
Impossible_Yam4412 / Reddit
To make matters worse, Mary said that food items in her cupboards "feel damp" and start to grow mold within a few days.
While she isn't sure why it's become so much worse recently, Mary wonders if there might be a potential leak in the wall. She cleans and disinfects regularly, uses a dehumidifier, leaves the extractor fan running in the bathroom, and keeps doors open.
When it started to become a serious problem in early June, Mary contacted the leasing office and sent them photos of the mold, asking what they would do to help.
Mold spots on Mary's mattress and a wine bottle.
Mold spots on Mary's mattress and a wine bottle.
Impossible_Yam4412 / Reddit
"They responded six days later and said they'd sent maintenance to look, but that they haven't seen any indication of a leak. They said it was 'organic growth' and recommended getting a dehumidifier, keeping the AC on auto, and keeping my doors open, which I have always done," Mary said.
She continued: "They said it's mildew because it's not on any walls or ceilings. I responded and told them it is indeed on the walls and ceilings, and that I have already been doing their recommendations and it's only worsening. I formally requested to be let out of my lease due to uninhabitable conditions—they did not respond. I followed up nine days later stating how bad it is and that I cannot live there anymore."
When she called the office again, one of the leasing agents told Mary that they'd "brought in a third party professional" to inspect the property. At the time of writing, Mary hasn't received a report from the maintenance team or the third party.
Newsweek has contacted the building management company via email.
Mary told Newsweek: "She was blaming me, saying that the 'organic growth' and 'mildew' is not mold, and is caused by me sometimes opening my windows in my living room. She said it's my fault and my responsibility, but was also saying their team would help, which doesn't make sense."
Following the back and forth, Mary shared several images of the mold on Reddit (posting as user Impossible_Yam4412) to ask what internet users think it is. The post has horrified many, leading to over 240 comments from people who agreed with Mary that it is in fact mold.
Seeing the online support has been somewhat comforting for Mary, who has received plenty of suggestions about what she could do next.
The experience has left Mary fearing for her health, as she wonders what she and her cat have been inhaling. She also discovered that the previous tenant moved out after developing "severe health concerns" due to mold.
Although her lease doesn't end until December 2025, Mary is planning to move elsewhere as soon as possible. "Even if they make me pay the $3,000 to break my lease, I have no choice. This apartment is not habitable," she said.
She is still waiting for the leasing office and management company to help, but she believes they are delaying the inevitable as they keep ignoring her calls and emails.
"They don't care about me or my health, just my rent," Mary said.
Among the hundreds of comments on the Reddit post, one person responded: "Omg get out of there that is a health hazard!"
Another Reddit user wrote: "I'm not sure that they should blame it on you, especially if the previous tent moved because of mold. Your landlord might have painted over the mold instead of having the apartment cleaned. I've heard of some landlords doing this."
While another person added: "I'm just surprised you said you have stayed there for three years now. I would have definitely left!"
Do you have any viral videos or pictures that you want to share? We want to see the best ones! Send them in to life@newsweek.com and they could appear on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
3 hours ago
- Newsweek
Ice Cream Recall Map Shows States With New Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. DFA Dairy Brands, LLC, is recalling the Friendly's brand of Cookies & Cream ice cream due to undeclared soy and wheat concerns. Newsweek reached out to the company via email on Wednesday for comment. Why It Matters Numerous recalls have been initiated this year due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. People with a wheat or soy allergy could experience a "serious or life-threatening allergic reaction if they consume these products," the FDA warns. What To Know In the alert, the FDA says that the recalled products were packaged mistakenly in Friendly's Vanilla Bean cartons with a Cookies & Cream lid. The recalled products were distributed through UNFI to retail locations in Pennsylvania, Maryland and Virginia. Below is a map showing the states impacted by the recall: The ice cream was sold in 48-fluid ounce containers with a best-by date of November 26, 2025. No other Friendly's products are impacted by the recall, the FDA alert notes. What People Are Saying The FDA in the alert, in part: "The voluntary recall was initiated after it was discovered that a limited quantity of Cookies & Cream ice cream was mistakenly packaged in Friendly's Vanilla Bean ice cream cartons that did not identify the soy and wheat ingredients. No illnesses or adverse reactions have been reported. This recall is being made with the knowledge of the U.S. Food and Drug Administration." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall; the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall. "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled product are urged to return the ice cream to the original place of purchase for a refund, the FDA alert notes. People with additional questions may contact DFA Dairy Brands, LLC, via phone at 800- 587-2259. Further recalls or updates are possible as investigations continue, and consumers are encouraged to monitor FDA alerts for developments.
Newsweek
12 hours ago
- Newsweek
Donald Trump Threatens 250% Tariff on Pharmaceuticals
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has said that tariffs on pharmaceutical imports could eventually reach up to 250 percent, as his administration works to lower prescription prices for Americans. During an interview with CNBC on Tuesday, the president said he will initially impose a "small tariff on pharmaceuticals," which will rise to 150 percent "in one year, one and a half years maximum," before then eventually jumping to 250 percent. Newsweek reached out to the White House via email for comment. Why It Matters The United States imports a significant amount of pharmaceuticals each year—over $200 billion in 2024, according to the Observatory of Economic Complexity. Should Trump follow through on ramping up these duties, the highest he has threatened on the industry to date, experts believe this could result in significant increases to drug prices in the U.S. However, some health policy experts told Newsweek this could also help rebalance the global drug supply chain to better favor American customers. What To Know Trump said that the tariffs are intended to encourage pharmaceutical companies to move their operations to the U.S.—"because we want pharmaceuticals made in our country"—and to minimize reliance on Europe. He had previously threatened to place 200 percent tariffs on pharmaceuticals in July, but said he would give the industry time before this change came into effect. Trump's threats of pharmaceutical tariffs have raised concerns among experts that these could lead to increased costs and medication shortages in the U.S. In April, the UNC Center for the Business of Health published a report warning that these effects would be especially significant for generic drugs, which are more likely to be imported and operate on lower profit margins than brand-name medications. "A 250 percent tariff on pharmaceuticals would have a significant impact on drug prices," said health economist Jeromie Ballreich. Ballreich told Newsweek that, for branded pharmaceuticals, higher costs from the tariffs will be "passed on to consumers and most likely will be indirect through higher prescription drug insurance premiums." Major pharmaceutical companies across the world saw their shares fall on Wednesday following Trump's announcement. England-based AstraZeneca was down by 1.1 percent, Indiana-based Eli Lilly by 2.3 percent, and Germany-based Bayer AG by nearly 10 percent as of 11:20 ET. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, 2025. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, latest threat comes as the industry braces for the outcome of an ongoing probe by the Commerce Department into the national security implications of America's medicinal imports. The investigation was launched in April by Commerce Secretary Howard Lutnick under Section 232 of the 1962 Trade Expansion Act. Trump did not provide many specifics, such as whether certain classes of pharmaceuticals would be exempt, beyond stating that these tariffs are separate from the country-specific duties that came into effect last week. However, the announcement appears to contradict the terms of the European Union deal struck in July, which the European Commission president said placed a 15-percent tariff "ceiling" on multiple sectors, including pharmaceuticals. Experts had already warned that the 15 percent tariff outlined in the EU trade deal could end up costing the pharmaceutical industry billions. The cost implications could also be seen as conflicting with the administration's separate attempts to lower the price of prescription drugs. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, 2025. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, May, Trump signed an executive order directing the Secretary of Commerce and U.S. Trade Representative to "ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States." It also proposed that the U.S. be given Most-Favored-Nation (MFN) status, which would require drug companies to offer Americans the same lowest price that drugs are sold for in other countries. Trump followed this up by sending letters to 17 of the world's largest pharmaceutical companies on July 31, outlining steps they must take within 60 days to lower prescription prices for U.S. customers. These include extending MFN pricing to Medicaid, guaranteeing MFN pricing for new medications and negotiating "harder with foreign freeloading nations." The letters also call on the companies to expand direct-to-consumer distribution models to ensure customers "get the same low MFN prices that manufacturers already offer to third-party payers." "At face value, these tariffs are contradictory to his efforts to lower domestic prices," Ballreich told Newsweek. "However, if the tariffs are used as a threat to get drug companies to comply to his administration's [executive orders], including the recent letters to pharmaceutical CEOs, then I think we could see some changes to the pharmaceutical market, which will lower domestic drug prices." Several drugmakers, including Eli Lilly, AstraZeneca and Johnson & Johnson, have also pledged to expand their U.S. manufacturing presence. Prior to the letters being sent, but amid this pressure from the administration, a number had also announced they would be reducing some U.S. drug prices. Health policy analyst Mariana Socal warned that beyond potential cost implications, the tariffs could significantly disrupt the drug development pipeline, potentially jeopardizing the release of new medications. "Aside from the problem of added costs, the uncertainty introduced by tariff policies is detrimental in and of itself to the pharmaceutical market," she told Newsweek, noting that only around one in 10,000 investigated compounds make it to pharmacy shelves, and only do so after decades of work. "Any added uncertainty is likely to be detrimental to this industry, including disincentivizing investors from supporting this industry and pharmaceutical manufacturers from continuing to look for cures," she said. What People Are Saying Health economist Jeromie Ballreich told Newsweek: "This tariff could really disrupt the U.S. prescription drug market, especially the Medicare part D market, where the party plans will be on the hook for the higher price prices and result in significant premium increases to offset these higher prices. Given that, I don't think it's likely that this massive tariff will occur, but rather is a threat to force companies to find solutions based on the executive orders and his recent letters to pharmaceutical CEOs." Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, told Newsweek: "It is critical to continue to identify solutions to lower drug prices in America and improve drug affordability for Americans. However, it is unclear how tariffs would advance affordability. On the opposite, tariffs can be understood as a hidden tax." "In the short term, the likelihood that added costs from tariffs will be passed through to consumers can be reduced by existing contractual agreements with supply chain participants such as distributors and group purchasing organizations, which can protect buyers from price increases for 1-3 years," she added. "However, even if the added cost of tariffs would not necessarily be passed-through to patients in the short term, it could raise costs in the long run." What Happens Next On Sunday, Trump said he would be announcing tariffs on the industry "within the next week or so."
Newsweek
13 hours ago
- Newsweek
Alzheimer's: Scientists Discover What Sparks Disease
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Lithium deficiency in the brain could be a cause of Alzheimer's disease—and a new potential target for treatment. Ten years in the making, this is the finding of researchers at Harvard Medical School who have revealed how lithium plays an essential role in brain function and may provide resistance against brain aging and Alzheimer's. Lithium is a chemical element, currently used as medicine to treat mood disorders like mania and bipolar disorder. "Most people associate lithium with psychiatric treatment. Our study shows, for the first time, that naturally occurring lithium plays a crucial role in maintaining brain health during aging—even at concentrations far below those used in clinical psychiatry," study authors Bruce Yankner and Liviu Aron told Newsweek. The findings are based on a series of experiments in mice and on analyses of human brain tissue and blood samples from individuals in various stages of cognitive health. Lithium carbonate tablet bottles on shelf. Lithium carbonate tablet bottles on shelf. Getty Images "We found that lithium is uniquely depleted in the brains of people with mild cognitive impairment—a precursor to Alzheimer's. This makes lithium deficiency one of the earliest biochemical signs of the disease, possibly years before clinical symptoms appear," the duo explained. "We also saw that higher endogenous lithium levels were associated with preserved cognitive function even in individuals without Alzheimer's. So, this isn't just about preventing disease—it's about supporting healthy brain aging in general. The new revelation helps to explain why some people with Alzheimer's-like abnormalities in the brain don't go on to develop the disease. While genetic and environmental factors play a role, scientists also haven't been able to suggest why some people with the same risk factors might develop it and others don't—until now. The scientists unearthed that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's. In mice, meanwhile, similar lithium depletion accelerated brain pathology (disease or abnormality) and memory decline. They also found reduced lithium levels stemmed from binding to amyloid plaques (misfolded proteins found between nerve cells found in the brains of people with Alzheimer's) and impaired uptake in the brain. One pair of boxes shows fewer green amyloid clusters on the left and more on the right. Another pair of boxes shows a dim arc of purple and red tau on the left and a... One pair of boxes shows fewer green amyloid clusters on the left and more on the right. Another pair of boxes shows a dim arc of purple and red tau on the left and a brighter arc on the right. More Yankner Lab In their final set of experiments, they found a new lithium compound that avoids "capture" by amyloid plaques restored memory in mice. "In people that start experiencing memory loss, the so-called mild cognitive impairment, lithium gets trapped by amyloid plaques—reducing its availability just when it's most needed to protect against inflammation and neurodegeneration," Yankner and Aron explained. "This creates a self-perpetuating feedback loop of worsening pathology and accelerating disease progression and memory loss." This all ties together decades-long observations in patients and provides a new theory of the disease and strategy for early diagnosis, prevention and treatment, according to the researchers. Recently developed treatments that target amyloid beta (a key component of the amyloid plaques) typically don't reverse memory loss and only modestly reduce the rate of decline. "The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach," said Yankner in a statement. Researchers had previously found lithium to be the only metal that had markedly different levels across people with and without Alzheimer's at different stages. But Yankner added in a statement, "Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C. "It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug." Previous population studies have shown that higher lithium levels in the environment, including in drinking water, tracked with lower rates of dementia. Woman hugging her elderly mother. Woman hugging her elderly mother. PIKSEL/Getty Images Yankner's team demonstrated in mice that lithium depletion isn't just linked to Alzheimer's, it actually helps drive it. This raises hope that one day lithium could be used to treat the disease in its entirety rather than focusing on a single factor like amyloid beta or tau (another Alzheimer's-associated protein), Yankner said. Crucially, the researchers discovered that as amyloid beta begins to form deposits in the early stages of dementia in both humans and mouse models, it binds to lithium, reducing lithium's function in the brain. The reduced levels of lithium affect all major brain cell types and, in mice, lead to changes similar to those seen in Alzheimer's disease, including memory loss. Treating mice with the most potent amyloid-evading compound, called lithium orotate, reversed Alzheimer's pathology, prevented brain cell damage and restored memory. While the findings need to be confirmed in humans through clinical trials, they suggest that measuring lithium levels could help screen for early Alzheimer's. They also highlight the importance of testing amyloid-evading lithium compounds for treatment or prevention. While other lithium compounds are already used to treat bipolar disorder and clinical depression, they are given at much higher concentrations that can be toxic to some people, the researchers flag. Yankner's team discovered lithium orotate is effective at one-thousandth that dose— enough to mimic the natural level of lithium in the brain. Mice treated for nearly their entire adult lives showed no evidence of toxicity, the study found. If further studies confirm these findings, the researchers say lithium screening through routine blood tests may one day offer a way to identify individuals at risk for Alzheimer's who would benefit from treatment to prevent or delay disease onset. "Our study adds to growing evidence that Alzheimer's may be preventable—with something as simple as keeping brain lithium at healthy levels as we age," said Yankner and Aron. "Clinical trials [on humans] could test the impact of low-dose supplementation on cognitive health and dementia risk." Before lithium is proved to be safe and effective in protecting against neurodegeneration in humans, Yankner emphasized that people should not take lithium compounds on their own. Do you have a health story to share with Newsweek? Do you have a question about Alzheimer's? Let us know via health@ Reference Aron, L., Ngian, Z. K., Qiu, C., Choi, J., Liang, M., Drake, D. M., Hamplova, S. E., Lacey, E. K., Roche, P., Yuan, M., Hazaveh, S. S., Lee, E. A., Bennett, D. A., & Yankner, B. A. (2025). Lithium deficiency and the onset of Alzheimer's disease. Nature.
